The Effect of Medical Therapy on Reducing the Risk of Pacing Induced Cardiomyopathy

Mahdi S Agha,Christopher L Schaich,Rishi Rikhi,Krupal Hari,George M Bodziock,Prashant D Bhave
DOI: https://doi.org/10.1101/2024.07.10.24310243
2024-07-11
Abstract:Background: High right ventricular (RV) pacing burden can result in pacing-induced cardiomyopathy (PICM). Objectives: To investigate whether ACE inhibitors (ACEI), angiotensin receptor blockers (ARB), and beta blockers (BB) reduce the risk of PICM in patients with high RV pacing burden. Methods: This was a single center, retrospective study which included patients with normal ejection fraction (EF) and complete heart block who underwent pacemaker implantation between 1992 and 2013. The medical therapy group included patients who received ACEI/ARB, BB, or combination of these classes. The control group received neither ACEI/ARB nor BB. The primary endpoint was PICM, defined as upgrade to a biventricular device or reduction in EF to ?40% without another etiology identified. Fine-Gray subdistribution hazard models accounting for death as a competing risk were used to determine the relationship between medical therapy (ACEI/ARB, BB, or combination) and cumulative incidence of PICM. Results: The study included 642 patients (mean [SD] age 71 [14] years; 51% women). Over 10 years of follow-up, 76 (11.8%) patients received ACEI/ARB therapy only; 49 (7.6%) received BB therapy only; and 86 (13.4%) were exposed to both. PICM occurred in 10 of 211 patients in the medical therapy group (4.7%) and in 30 of 431 in the control group (7.0%). In adjusted analyses weighted for group-switching, the risk of PICM was significantly lower in the medical therapy group compared to the control group (HR 0.59, 95% CI 0.45 - 0.77). Patients exposed to combination therapy had the lowest risk (HR 0.46, 95% CI 0.31 - 0.69). Conclusion: In patients with high RV pacing burden, BB therapy alone or in combination with ACEI/ARBs appears to reduce the risk of PICM within 10 years of pacemaker implantation.
What problem does this paper attempt to address?
The issue addressed in this paper is whether the use of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta blockers (BBs), which are conventional drug therapies for heart failure, can reduce the risk of pacemaker-induced cardiomyopathy (PICM) in patients with high right ventricular (RV) pacing burden. The research method involved a retrospective analysis of data from patients who underwent pacemaker implantation between 1992 and 2013 and had normal ejection fraction and complete atrioventricular block. Patients who received these medications were compared with those who did not. The primary endpoint was defined as the occurrence of either upgrading to dual chamber device or a decrease in ejection fraction to below 40% as a result of PICM. A competing risk model considering death as a competing event was used to assess the relationship between medication therapy and cumulative incidence of PICM. The results showed a significant reduction in the risk of developing PICM in patients who received BB monotherapy or combination therapy with ACEI/ARB compared to the control group. The risk reduction was most pronounced in the combination therapy group. This suggests that BB therapy may help prevent the occurrence of PICM in patients with high RV pacing burden. However, the limitations of this study include its retrospective and single-center design, which calls for prospective randomized controlled trials to validate these findings. Additionally, the study population had a higher prevalence of cardiovascular risk factors such as hypertension, diabetes, chronic kidney disease, and atrial fibrillation, which could impact the results.